How to Prepare Registration Documentation for Overseas Marketing of Home Medical Devices?

To prepare registration documentation for overseas marketing of home medical devices, you must first match the product classification and registration pathway with the regulatory framework of each target country. Systematically compile technical files, quality system evidence, clinical evaluation data, labeling and instructions for use, and local agent arrangements. Determine whether the product is a medical device in the target jurisdiction—risk classes for pulse oximeters, blood pressure monitors, thermometers, and therapeutic devices vary significantly across the EU, US, Japan, China, Southeast Asia, the Middle East, and Latin America, directly affecting the pathway and required submissions. When reusing existing NMPA certificates, CE technical files, or FDA 510(k)/PMA documentation, assess gaps such as electromagnetic compatibility, biocompatibility, and software verification. Most GHWP member countries require a local agent or authorized representative who assumes post-market surveillance responsibility. Common risks include misclassification leading to deficiencies, insufficient clinical evidence, labeling not meeting local language and symbol requirements, and quality systems lacking target-country specifics (e.g., MDSAP, ISO 13485 plus local deviations). Plan your documentation package early, prioritize core performance verification and risk management reports, and then localize per country to avoid duplicate testing.

Compiled from the AIMEILI registration practice database, the medical device international registration knowledge base, and public regulatory information. Specific projects should follow the latest requirements of the target country's regulatory authority and your product's technical documentation.

Published: 2026-07-30 15:30; Updated: 2026-07-30 15:30

Key Summary

The core of preparing registration documentation is to align product classification and the registration pathway with the target country's regulatory framework. Use existing NMPA, CE, or FDA documentation only after identifying gaps. Most GHWP members require local representation. Plan a master documentation package and localize it for each market to avoid redundant testing.

Applicable Scenarios and Core Questions

Home medical devices include electronic blood pressure monitors, pulse oximeters, thermometers, glucose meters, oxygen concentrators, ventilators, physiotherapy devices, and rehabilitation equipment. Before starting overseas registration, answer three core questions: (1) Is the product a medical device in the target country? (2) Which risk class does it belong to? (3) Will the applicant be the manufacturer or a local agent? These answers define the scope and depth of the required documentation.

For example, the EU classifies pulse oximeters as Class IIa, requiring notified body review; the US FDA classifies them as Class II (510(k)) or Class III (PMA) depending on intended use; Japan requires PMDA certification. You cannot apply one country's classification to another—you must confirm each country individually.

Another key issue is whether existing domestic registration documents (such as NMPA registration certificates, product technical requirements, and test reports) can be used directly for overseas registration. NMPA files can serve as a foundation, but foreign regulators often have stricter requirements for performance verification, clinical evaluation, and risk management. For example, the EU MDR requires a more comprehensive Clinical Evaluation Report (CER) and Post-Market Clinical Follow-up (PMCF). You must assess conformity with international standards (IEC 60601 series, ISO 14971, ISO 10993, etc.), identify gaps, and supplement testing.

Registration Decision Logic

• Step 1: Confirm whether the product is a medical device. For instance, a smart wristband that only provides activity data may not be a medical device; but if it has ECG monitoring and is intended for diagnosis, it requires registration.
• Step 2: Determine the risk classification using the target country's rules. The EU uses MDR classification rules (based on invasiveness, duration of use, and energy mode); the US FDA classifies under 21 CFR 862-892; Japan uses JMDN; China uses the Medical Device Classification Directory.
• Step 3: Select the registration pathway. Low-risk products can often self-declare (e.g., EU Class I) or submit a simplified application (e.g., US 510(k) exemption); medium- to high-risk products require technical file review, and some countries require on-site inspections (e.g., Brazil ANVISA, Japan PMDA).
• Step 4: Evaluate the reusability of existing documentation. If you already have CE MDR technical files, FDA 510(k), or an NMPA certificate, preparation time can be significantly reduced; however, note country-specific requirements such as South Korea's additional electrical safety test (K-60601) or Saudi Arabia's SFDA registration plus local agent.
• Step 5: Identify the applicant entity. Most countries require the manufacturer to register, but you must designate a local authorized representative (e.g., EU, Saudi Arabia, Thailand); some countries allow overseas manufacturers to register directly (e.g., US, Canada).

Documentation and Evidence

A typical documentation package includes the following modules:

• Company qualification documents (business license, ISO 13485 certificate, MDSAP certification, etc.).
• Basic product information (name, model, working principle, intended use, contraindications, etc.).
• Risk management documents (risk management report and risk analysis table per ISO 14971).
• Product technical information (design description, drawings, list of critical components, software description, etc.).
• Performance verification and test reports (electrical safety, EMC, biocompatibility, performance testing, software verification, etc.).
• Clinical evaluation materials (clinical literature review, clinical trial reports, equivalent device comparison analysis, etc.).
• Labels and instructions for use (original and local language versions, compliant with local labeling regulations such as EU MDCG guidance or US FDA 21 CFR 801).
• Manufacturing information (production processes, quality control, sterilization validation, etc.).
• Post-market surveillance plan (PMS plan, PMCF plan, adverse event reporting procedures).
• Local agent/authorized representative information.

Establish a master technical file/design dossier and export country-specific subsets with localization (e.g., label language, certificate format, local-language instructions for use, and agency agreements).

Common Mistakes

• Misclassification: Judging a high-risk product as low-risk, leading to the wrong registration pathway and a return for reclassification, causing delays.
• Insufficient clinical evidence: Relying on domestic clinical reports that do not meet target country standards (e.g., GCP requirements, ethics review) or failing to provide sufficient equivalent device comparisons.
• Non-compliant labeling: Not using the local official language or symbols that do not conform to ISO 15223 or country-specific requirements (e.g., Japanese PMD Act requires manufacturer's address in Japanese).
• Incomplete risk management: Not covering all intended use scenarios and foreseeable misuse, or missing software/hardware-related hazards.
• Quality system not meeting target country requirements: For example, holding only ISO 13485 when the target country requires MDSAP (e.g., Canada, Brazil, Japan, US) or not including special process validation.
• Ignoring local agent and authorized representative responsibilities: Some companies discover after registration that the local agent did not fulfill PMS obligations, leading to certificate suspension.
• Missing post-market surveillance documents: Not preparing the PMS plan and Periodic Safety Update Report (PSUR) templates, resulting in additional information requests during review.
• Language translation errors: Inaccurate translations of instructions or labels can create safety hazards or compliance issues.

Company Preparation Checklist

• Confirm the target market list and registration priorities.
• Collect and update company qualification documents (business license, system certificates, MDSAP, etc.).
• Complete product classification assessments and confirm risk classes for each country.
• Prepare or update the risk management report per the latest ISO 14971 version.
• Organize product technical specifications, design drawings, and software descriptions (if applicable).
• Arrange or obtain performance test reports (electrical safety, EMC, biocompatibility, usability, etc.).
• Write or update the Clinical Evaluation Report (CER); conduct clinical trials or equivalence arguments if necessary.
• Create labels and instructions for use in multiple languages, compliant with local regulations.
• Ensure the quality system meets target country requirements; perform supplemental audits or gap analyses if there are differences.
• Sign agreements with local authorized representatives or agents, clarifying responsibilities and contract terms.
• Develop a post-market surveillance plan, including PMS, PMCF, PSUR, and adverse event reporting processes.
• Prepare registration application forms and supporting document packages in the required format for each country.

AIMEILI's Perspective

The areas companies most often misjudge are "classification" and "clinical evidence." Many home medical devices are managed as Class I or II domestically, but may fall into a higher class overseas. For example, a forehead thermometer that is Class I in China may be Class IIa in the EU and require notified body review. Also, many companies believe domestic clinical reports are sufficient, but overseas reviewers place extremely high demands on the independence and comparability of clinical evidence. For devices claimed to be equivalent, you must provide a detailed comparison of technical characteristics, materials, and functions.

The most important early action is to conduct a pre-classification assessment for each target country and commission a professional gap analysis to determine the difference between your existing documentation and the target country's requirements. This will allow you to plan supplemental testing and documentation. Reusable documents include: ISO 13485 certificate, MDSAP certification, IEC 60601 test reports (if version-consistent), ISO 14971 risk management reports (updated for the product lifecycle), and software verification documents.

Content that must be localized includes: labels and instructions for use (language, symbols, regulatory requirements), clinical evaluation reports (target-market epidemiology and clinical preferences), sections of the risk management report on user population and environment, and agent agreements and powers of attorney. Local agents, certificate control, changes, and renewals are critical: many companies lose their certificates because they do not understand the agent change process, or they fail to update technical files (e.g., critical component changes), triggering compliance problems.

We recommend establishing a multi-country registration master file platform, generating a difference table for each market, and having a regulatory team manage the change and renewal timeline centrally. This avoids redundant work and incomplete submissions.

Common Follow-up Questions

Q1: What test reports are typically required for overseas registration of a home pulse oximeter?

Generally, you need electrical safety testing (IEC 60601-1), electromagnetic compatibility testing (IEC 60601-1-2), biocompatibility testing (ISO 10993 series, including cytotoxicity, sensitization, and irritation), performance testing (oxygen saturation accuracy, heart rate accuracy, motion artifact verification), and usability testing (IEC 62366-1). Depending on the target country, you may also need software lifecycle documentation (IEC 62304) and wireless functionality testing. Some countries, such as Brazil and India, may require local laboratory testing.

Q2: If I already have CE MDR registration, can I use it directly for Latin American or Southeast Asian registration?

It can save significant time, but it cannot be used directly. CE technical files can serve as a foundation, but localization is required: translate labels into the local language, adjust the risk management report for population-specific differences (e.g., high altitude, humid heat), incorporate local epidemiological data into the clinical evaluation, and confirm the local power grid parameters (voltage, frequency) for electrical safety testing. Additionally, most Latin American and Southeast Asian countries require the manufacturer's ISO 13485 certificate and a local agent authorization; some require on-site inspections or GMP certificates. We recommend using the CE file as the core and building a multi-country difference analysis table, then supplement documents country by country.

Q3: If our company does not have ISO 13485, can we ask an OEM factory to register?

Yes, but you must consider the legal entity. If your company is the brand owner and the OEM factory is the manufacturer holding the system certificate, you need an agreement that clearly defines the registration applicant and post-market responsibilities. Most countries require the registration applicant to be the manufacturer (i.e., the party responsible for design, production, and final inspection). Therefore, the brand owner may need to act as an "authorized representative" or "legal manufacturer" to apply for registration. We recommend consulting a professional agency to determine the optimal structure and avoid unclear responsibilities. If the OEM factory holds ISO 13485, ensure the scope covers your design control, purchasing, and distribution activities; an extension audit may be necessary.

Implementation Recommendations

In practice, break this question into five tasks: regulatory judgment, documentation preparation, evidence reuse, localization conversion, and post-market maintenance. Do not let a single department temporarily compile files. This approach identifies documentation gaps earlier and gives sales, R&D, quality, and regulatory teams a shared understanding of the target countries' requirements.

If you plan to enter multiple markets simultaneously, first build a unified core technical file, then add authorizations, labels, translations, forms, and local agent materials for each country. The efficiency of multi-country registration often depends on whether the upfront documentation framework is unified, not on how quickly any single country is submitted.

Follow this sequence:

• Confirm whether the product falls under medical device regulatory oversight in the target countries.
• Confirm the risk class, registration pathway, and applicant entity.
• Verify that technical files, quality systems, and clinical evidence support each other.
• Clarify local agents, authorized representatives, and certificate control.
• Establish mechanisms for post-market changes, renewals, and vigilance event handling.

Additional Implementation Points

When addressing "how to prepare registration documentation for overseas marketing of home medical devices," manage regulatory judgment, documentation evidence, applicant entity, time to market, and post-market responsibilities in a single project table. Otherwise, the regulatory team may focus only on documents, the sales team only on time to market, and the quality team may not understand target market requirements, resulting in a disconnect between the registration pathway and documentation preparation.

If the target market is a GHWP member or closely aligned with international rules such as IMDRF, ISO 13485, ISO 14971, and UDI, prioritize identifying reusable documentation, then decide what needs local translation, additional declarations, retesting, or signatures from local agents. This sequence is more stable and cost-effective than simply collecting documents by country list.

At the project execution level, retain at least the following records: product classification basis, technical file versions, label and IFU versions, test report model coverage, clinical evidence sources, local agent communication logs, and deficiency response records. These records will directly affect your ability to quickly explain product compliance status during renewals, changes, unannounced inspections, or post-market events.

• Confirm the product's intended use and target market regulatory status.
• Confirm the risk class, registration pathway, and applicant entity.
• Confirm whether core technical files can be reused across markets.
• Confirm localization requirements, label language, and authorization documents.
• Confirm post-market surveillance, change, and renewal responsibilities.

Continue Reading

• How to handle inconsistent quality system certificates for POCT product overseas registration?
• How to determine product classification for home medical device overseas registration?
• Common reasons for additional information requests in home medical device registration?
• How to prepare registration documentation for POCT products?
• How to organize the model/specification matrix for overseas medical device registration?
• Why is the registration cycle for POCT products extended?
• Common reasons for additional information requests in POCT product registration?
• How to conduct post-market surveillance for POCT products?